RP1

RP1 (vusolimogene oderparepvec) is Replimune's genetically engineered herpes virus, injected directly into tumors so the virus kills cancer cells and drags the immune system into the fight. The lead program pairs RP1 with Bristol Myers Squibb's checkpoint inhibitor nivolumab in advanced melanoma patients who have progressed on prior anti-PD-1 (and typically anti-CTLA-4) therapy, a group with few real options [1]. Replimune's original Biologics License Application (BLA, the FDA filing required to market a biologic drug) under the accelerated approval pathway was rejected by the FDA in a Complete Response Letter (CRL, an official FDA refusal-to-approve letter) issued July 22, 2025, and a second CRL followed on April 10, 2026 [3][5][11]. A third resubmission was accepted in June 2026 under a Class 1 review, with an August 2, 2026 PDUFA target action date and an Advisory Committee meeting scheduled for late July 2026 [12]. The company is also running the confirmatory Phase 3 IGNYTE-3 trial (NCT06264180) to salvage the melanoma opportunity if accelerated approval fails again [2]. A second front in cutaneous squamous cell carcinoma is being explored in a Phase 1 study in solid organ transplant recipients (NCT04349436) [4]. The commercial stakes are unusually concentrated: Replimune has no approved products, and RP1 is essentially the company's entire near-term valuation.

RP1 is a novel biologic with no approvals anywhere. The most advanced use is RP1 plus nivolumab in advanced melanoma after failure of anti-PD-1 (and, for most patients, anti-CTLA-4) therapy. Replimune filed a BLA under accelerated approval on the strength of the single-arm IGNYTE-1 Phase 1/2 data (confirmed overall response rate 33.6%, n=140, median duration of response 21.6 months) [1]. The FDA issued a first CRL on July 22, 2025 stating that IGNYTE-1 was not an adequate and well-controlled study, in part because the patient population was too heterogeneous for a single-arm accelerated filing [3][5]. After a first resubmission accepted in October 2025 with an April 10, 2026 PDUFA date, the FDA issued a second CRL on that same date, citing a new review team that had not met with the company during the review and appearing (per Replimune) to contradict prior FDA feedback from Type A and pre-BLA meetings [11]. A third resubmission was accepted in June 2026 as a Class 1 response, with a PDUFA target action date of August 2, 2026 and an FDA Advisory Committee (AdCom) scheduled for late July 2026 [12]. The company holds Fast Track designation for the melanoma program [6]. In parallel, the confirmatory Phase 3 IGNYTE-3 trial (NCT06264180) is recruiting toward 400 patients with overall survival as the primary endpoint [2]. A small Phase 1 program in cutaneous squamous cell carcinoma in organ transplant recipients (NCT04349436) is active but not recruiting, and an academic Phase 2 in angiosarcoma with pembrolizumab (NCT06898970) is ongoing [4][7]. IGNYTE-3 has not been publicly guided to a specific readout quarter, but on current enrollment pace the primary analysis is unlikely before 2028.

Oncolytic viruses are engineered pathogens that selectively multiply inside cancer cells and rupture them. Cancer cells are unusually vulnerable to viruses because they have downregulated the interferon defenses a normal cell uses to fight infection, so a virus that has been weakened just enough to spare normal tissue can still tear through a tumor. RP1 is a modified herpes simplex virus type 1 with two extra features added: a gene for GM-CSF (a signaling protein that summons dendritic cells, the immune system's antigen-presenting scouts, to the wreckage), and a fusogenic glycoprotein from gibbon ape leukemia virus (GALV-GP R minus) that makes infected tumor cells fuse together into giant syncytia before dying, releasing far more tumor antigen than a normal lytic burst [8]. The debris then teaches T cells what tumor cells look like, and adding nivolumab releases the PD-1 brake so those T cells can kill. The mechanism has real precedent: Amgen's talimogene laherparepvec (Imlygic), also an HSV-1 armed with GM-CSF, was approved in melanoma in 2015 [9]. But Imlygic has been a commercial disappointment, generating roughly $115 to $120 million per year in global net sales during 2019 to 2021 despite Amgen's large sales infrastructure, largely because clinicians found intratumoral dosing awkward and pembrolizumab combinations never demonstrated systemic benefit convincingly [13]. RP1's addition of the fusogenic protein is the differentiator Replimune is betting on.

IGNYTE-3 (NCT06264180) is a randomized, open-label Phase 3 trial in advanced melanoma patients who have progressed on both anti-PD-1 and anti-CTLA-4 therapy (administered either as a combination regimen such as nivolumab plus ipilimumab, or in sequence), testing RP1 plus nivolumab against physician's choice of nivolumab plus relatlimab, nivolumab plus ipilimumab, or chemotherapy [2]. Patients not candidates for anti-CTLA-4 due to documented comorbidities or prior immune-related adverse events are also eligible if they have progressed on anti-PD-1 alone. Target enrollment is 400 patients, primary endpoint is overall survival, and the trial is actively recruiting under Replimune sponsorship. The heterogeneous comparator arm is a double-edged sword: it reflects real clinical practice and was chosen partly to answer the FDA's exact critique of IGNYTE-1, but it also introduces variance and complicates powering. Note that a patient who has already failed nivolumab plus ipilimumab as their combination front-line would not typically be re-randomized to the same regimen; the ipilimumab-containing physician's choice options are most relevant for the subset with sequential prior exposure or CTLA-4-naive status via the exception criterion. Overall survival in this refractory population is historically dismal (median under a year), so an event-driven analysis should read out in a reasonable timeframe, but Replimune has not publicly committed to a specific readout quarter. The Phase 1 cutaneous squamous cell carcinoma program in transplant recipients (NCT04349436) is small (n=69) and investigator-focused, useful for signal-generating in a niche population where immune checkpoint inhibitors are contraindicated because of rejection risk [4]. The angiosarcoma Phase 2 (NCT06898970, n=18) is an academic effort at the University of Iowa and is safety-lead-in stage, not a commercial priority [7].

Our model estimates a 5% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by the sponsor's thin or weak approval record, smaller-than-typical enrollment for this phase, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Regulatory risk is the largest and most specific: the FDA has now told Replimune twice that the accelerated-approval case is inadequate, and the July 2026 AdCom is a binary event before the August 2, 2026 PDUFA date [11][12]. Efficacy risk sits close behind. IGNYTE-1's 33.6% confirmed ORR in a single-arm cohort looks strong on paper, but response rate is a weak proxy for survival in melanoma, and post-anti-PD-1 patients have unpredictable natural histories that can flatter uncontrolled data [1]. Safety risk is mechanism-based rather than idiosyncratic: intratumoral live-virus therapy has a real profile of injection-site reactions, systemic viral symptoms, and rare herpetic complications, and the transplant investigator-initiated trial (IIT, an academic-run study rather than a company-sponsored one) is the highest-risk safety setting. Commercial risk is illustrated by Imlygic itself, which despite an approval and Amgen's large sales force generated only roughly $115 to $120 million per year during its post-launch peak, because intratumoral injection is logistically painful for community oncologists and payers push back on high-cost regional therapies when systemic checkpoint inhibitors are the default [13]. Even a clean IGNYTE-3 win puts RP1 into a market where anti-PD-1 combinations, TIL therapy (lifileucel), and emerging TCR-T assets all compete for the same shrinking pool of refractory patients. Deal-structure note: the Bristol Myers Squibb collaboration for nivolumab supply is a non-exclusive, royalty-free clinical trial supply agreement under which BMS provides nivolumab at no cost and has no further development or commercialization obligations, so Replimune retains 100% of RP1 economics on approval, but bears the full commercial infrastructure build [14]. Execution risk is concentrated: as of March 31, 2026 Replimune held $268.9 million in cash, cash equivalents, and short-term investments (down from $483.8 million a year earlier), and management guides runway into the first quarter of calendar 2027, which is a tight window to run Phase 3 while working through the regulatory process [15].

Worth watching, with the caveat that this is a binary equity story dressed up as a science story. Replimune's market capitalization is a used bet on the July 2026 AdCom, the August 2, 2026 PDUFA decision, and IGNYTE-3 as the fallback [11][12]. The specific data points that would flip this from noise to signal are: (1) the AdCom vote outcome and briefing documents, both public via the FDA before the meeting, (2) accelerated approval or a third CRL on August 2, 2026, (3) any interim futility or efficacy analysis in IGNYTE-3, and (4) mature overall survival data from the IGNYTE-1 cohort that either holds up or decays as follow-up lengthens. Check back after each Replimune 8-K filing (an SEC disclosure of material events between quarterly reports) and at ASCO (American Society of Clinical Oncology) or SITC (Society for Immunotherapy of Cancer), where the company typically presents updated melanoma data. The cutaneous squamous cell carcinoma and angiosarcoma programs are scientifically interesting but not commercially load-bearing for the near-term thesis. The bigger question for readers is whether oncolytic virology as a category deserves another look after a decade of Imlygic being a cautionary tale; RP1 is the best-designed test of that question currently in the clinic, but that is a low bar. Because BMS supplies nivolumab royalty-free with no downstream economics, Replimune (or an acquirer) captures the full upside of an RP1 approval, which sharpens the binary. A clean win at AdCom plus approval revives the category and the equity. A third CRL likely closes the book on armed HSV for a generation and stresses cash runway into 2027. This is not investment advice.